| PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects (NCT02807077) | CTI BioPharma | 2014-11-01 |
| Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children. (NCT02280759) | Medical University of Warsaw | 2014-11-01 |
| Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra (NCT02270918) | Thomas Jefferson University | 2014-11-01 |
| Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 (NCT02307461) | SecuraBio | 2014-11-01 |
| A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (NCT02310750) | Pfizer | 2014-11-01 |
| Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (NCT02374385) | Dalhousie University | 2014-11-01 |
| An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience. (NCT02325011) | Jazz Pharmaceuticals | 2014-11-01 |
| Minimally Invasive Imagery With Indocyanine Green (NCT02621268) | University of Pennsylvania | 2014-11-01 |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (NCT02275286) | Grupo Espanol de Investigacion en Sarcomas | 2014-11-01 |
| AZD8108 SAD/MAD in Healthy Volunteers (NCT02248818) | AstraZeneca | 2014-11-01 |
| A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects (NCT02286882) | Pfizer | 2014-11-01 |
| Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg (NCT02485041) | SK Chemicals Co., Ltd. | 2014-11-01 |
| GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration (NCT02302976) | Yale University | 2014-11-01 |
| Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer (NCT02101593) | Polaris Group | 2014-11-01 |
| A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE) (NCT02250820) | Children's Hospital Medical Center, Cincinnati | 2014-11-01 |
| A Phase 1, Single and Multiple Dose Study of TAK-137 (NCT02322606) | Takeda | 2014-11-01 |
| Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma (NCT02173093) | University of Virginia | 2014-11-01 |
| A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions (NCT02465866) | Charleston Laboratories, Inc | 2014-11-01 |
| Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support (NCT02230722) | San Francisco Veterans Affairs Medical Center | 2014-11-01 |
| Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors (NCT02318329) | Five Prime Therapeutics, Inc. | 2014-11-01 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy (NCT02223182) | DBV Technologies | 2014-11-01 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects (NCT02291991) | Genexine, Inc. | 2014-11-01 |
| VSV-ZEBOV Geneva Vaccine Trial (NCT02287480) | University Hospital, Geneva | 2014-11-01 |
| Parametric Testing of Direct Physiological Effects of Transcutaneous Vagus Nerve Stimulation (tVNS) in Healthy Controls (NCT02835885) | Medical University of South Carolina | 2014-11-01 |
| Glutathione and Function in HIV Patients (NCT02348775) | Baylor College of Medicine | 2014-11-01 |
| Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (NCT02115672) | Sheba Medical Center | 2014-11-01 |
| Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (NCT02266355) | Yale University | 2014-11-01 |
| Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors (NCT02285101) | Bio-Cancer Treatment International Limited | 2014-11-01 |
| RTA 408 Capsules in Patients With Melanoma - REVEAL (NCT02259231) | Biogen | 2014-10-31 |
| Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants (NCT02127801) | Regeneron Pharmaceuticals | 2014-10-31 |
| Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers (NCT02271984) | Merck KGaA, Darmstadt, Germany | 2014-10-31 |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer (NCT02178436) | Mohammed Najeeb Al Hallak | 2014-10-31 |
| Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (NCT02264678) | AstraZeneca | 2014-10-31 |
| Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors (NCT02267967) | Hutchison Medipharma Limited | 2014-10-31 |
| Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma (NCT02097134) | Children's Oncology Group | 2014-10-31 |
| Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers (NCT02153437) | Bristol-Myers Squibb | 2014-10-30 |
| Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) (NCT02282371) | Memorial Sloan Kettering Cancer Center | 2014-10-30 |
| Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access (NCT02280824) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-10-30 |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis (NCT02245867) | Alexion Pharmaceuticals, Inc. | 2014-10-30 |
| BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer (NCT02155088) | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-30 |
| A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020) (NCT02411929) | Merck Sharp & Dohme LLC | 2014-10-29 |
| Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients (NCT02069704) | mAbxience Research S.L. | 2014-10-29 |
| Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease (NCT01795573) | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-29 |
| Treatment of Patients With Non-healing Wounds and Trophic Ulcers Using Autologous Dermal Fibroblasts (NCT04483934) | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 2014-10-28 |
| Phase 1 Study of E7090 in Subjects With Solid Tumor (NCT02275910) | Eisai Co., Ltd. | 2014-10-28 |
| A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine (NCT02693652) | Aribio Lab Co., Ltd. | 2014-10-28 |
| A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (NCT02124850) | Celgene | 2014-10-28 |
| Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) (NCT02103478) | Astex Pharmaceuticals, Inc. | 2014-10-28 |
| Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation (NCT02218723) | GlaxoSmithKline | 2014-10-28 |
| Allogeneic Virus-specific T Cell Lines (VSTs) (NCT02510417) | Catherine Bollard | 2014-10-28 |
| Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED) (NCT02272270) | University of Utah | 2014-10-27 |
| Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery (NCT02278744) | Memorial Sloan Kettering Cancer Center | 2014-10-27 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants (NCT02275065) | Gilead Sciences | 2014-10-24 |
| Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis (NCT02243306) | GlaxoSmithKline | 2014-10-24 |
| Pilot Study of DRibble Vaccine for Prostate Cancer Patients (NCT02234921) | UbiVac | 2014-10-24 |
| Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma (NCT02022644) | University of California, San Francisco | 2014-10-23 |
| Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor (NCT02250170) | Korea Otsuka Pharmaceutical Co., Ltd. | 2014-10-23 |
| Food Effect Study With BMS-955176 (NCT02273947) | ViiV Healthcare | 2014-10-23 |
| Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide (NCT02282904) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-23 |
| A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) (NCT02259114) | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-23 |
| Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1 (NCT02179034) | Yale University | 2014-10-23 |
| A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC (NCT01395641) | National Taiwan University Hospital | 2014-10-22 |
| A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS (NCT02488408) | BerGenBio ASA | 2014-10-22 |
| AZD9496 First Time in Patients Ascending Dose Study (NCT02248090) | AstraZeneca | 2014-10-22 |
| A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma (NCT02259010) | Millennium Pharmaceuticals, Inc. | 2014-10-22 |
| Hypoxia and Inflammatory Injury in Human Renovascular Hypertension (NCT02266394) | Mayo Clinic | 2014-10-21 |
| A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196 (NCT04867941) | Acerta Pharma BV | 2014-10-21 |
| Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) (NCT02191891) | Boehringer Ingelheim | 2014-10-21 |
| A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers (NCT03340870) | GE Healthcare | 2014-10-20 |
| A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants (NCT06004960) | Amgen | 2014-10-20 |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells (NCT02274506) | M.D. Anderson Cancer Center | 2014-10-20 |
| Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer (NCT02151019) | Cancer Trials Ireland | 2014-10-17 |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (NCT02222922) | Pfizer | 2014-10-17 |
| Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (NCT02146924) | City of Hope Medical Center | 2014-10-16 |
| Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT02206763) | Sierra Oncology LLC - a GSK company | 2014-10-16 |
| A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma (NCT02257567) | Hoffmann-La Roche | 2014-10-15 |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer (NCT02262741) | MedImmune LLC | 2014-10-15 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460) | M.D. Anderson Cancer Center | 2014-10-15 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies (NCT02175433) | Astellas Pharma Global Development, Inc. | 2014-10-14 |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers (NCT02280811) | National Cancer Institute (NCI) | 2014-10-14 |
| Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer (NCT02289690) | AbbVie | 2014-10-13 |
| A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors (NCT02261220) | MedImmune LLC | 2014-10-13 |
| Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) (NCT02269423) | Merck Sharp & Dohme LLC | 2014-10-13 |
| Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers (NCT02269293) | Memorial Sloan Kettering Cancer Center | 2014-10-13 |
| A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors (NCT02243917) | Cleave Biosciences, Inc. | 2014-10-11 |
| Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02227199) | University of Washington | 2014-10-10 |
| Human Immunity Against Staphylococcus Aureus Skin Infection (NCT02262819) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-10 |
| Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (NCT00862433) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2014-10-10 |
| A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas (NCT02130869) | St. Jude Children's Research Hospital | 2014-10-10 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT02166905) | Roswell Park Cancer Institute | 2014-10-10 |
| A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) (NCT02078960) | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-10-09 |
| Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases (NCT02187822) | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-09 |
| Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers (NCT02248259) | Boehringer Ingelheim | 2014-10-08 |
| COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients (NCT02253420) | Bayer | 2014-10-08 |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia (NCT02070458) | Case Comprehensive Cancer Center | 2014-10-08 |
| Lapatinib Plus Trametinib in KRAS Mutant NSCLC (NCT02230553) | The Netherlands Cancer Institute | 2014-10-07 |
| Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas (NCT02015819) | City of Hope Medical Center | 2014-10-07 |
| Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) (NCT02280408) | Merck Sharp & Dohme LLC | 2014-10-07 |
| A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264) (NCT02229877) | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-10-06 |